David Y. Mitchell, PhD, President, American Association of Pharmaceutical Scientists (AAPS)
"The pharmaceutical sciences are moving towards a new era and continue to adapt, evolve, and thrive despite some well-documented
growing pains. In the US and EU, there has been a pronounced shift to produce a leaner R&D process in large pharma, with a
move in workforce towards smaller companies, CROs, CMOs, and biotechnology startups. Whereas, in Asia Pacific, pharma is expanding
their footprint with clinical trials and new manufacturing sites, new government and private industry technical centers to
promote basic science research, and a goal of becoming one of the top research and marketing regions of the world.
"The industry now not only looks internally for new drug-development leads, but also towards smaller pharma, biotechnology
companies, and academic institutions, with their focused research programs and their quick and nimble operations, to bring
forth the potential medicines of tomorrow. Further, the pharma industry is expanding globally to leverage new markets and
low-cost alternatives for drug development.
"AAPS would like to congratulate Pharmaceutical Technology on its 35th anniversary. We're looking forward to continuing our strong partnership as we navigate these changes that will impact of
our industry for the next 35 years."
|
